WO2016077639A3 - Nanovesicular therapies - Google Patents

Nanovesicular therapies Download PDF

Info

Publication number
WO2016077639A3
WO2016077639A3 PCT/US2015/060466 US2015060466W WO2016077639A3 WO 2016077639 A3 WO2016077639 A3 WO 2016077639A3 US 2015060466 W US2015060466 W US 2015060466W WO 2016077639 A3 WO2016077639 A3 WO 2016077639A3
Authority
WO
WIPO (PCT)
Prior art keywords
nanovesicular
therapies
nanomembrane
methods
delivery complexes
Prior art date
Application number
PCT/US2015/060466
Other languages
French (fr)
Other versions
WO2016077639A2 (en
Inventor
Phillip SAMAYOA
Avak Kahvejian
Noubar Afeyan
Geoffrey Von Maltzahn
Original Assignee
VL27, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by VL27, Inc. filed Critical VL27, Inc.
Publication of WO2016077639A2 publication Critical patent/WO2016077639A2/en
Publication of WO2016077639A3 publication Critical patent/WO2016077639A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5063—Compounds of unknown constitution, e.g. material from plants or animals
    • A61K9/5068—Cell membranes or bacterial membranes enclosing drugs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/531—Stem-loop; Hairpin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Botany (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Compositions comprising nanomembrane delivery complexes, methods of generating nanomembrane delivery complexes, and methods of treating or preventing diseases, disorders or conditions therewith.
PCT/US2015/060466 2014-11-12 2015-11-12 Nanovesicular therapies WO2016077639A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462078967P 2014-11-12 2014-11-12
US62/078,967 2014-11-12

Publications (2)

Publication Number Publication Date
WO2016077639A2 WO2016077639A2 (en) 2016-05-19
WO2016077639A3 true WO2016077639A3 (en) 2016-06-30

Family

ID=54754773

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2015/060466 WO2016077639A2 (en) 2014-11-12 2015-11-12 Nanovesicular therapies

Country Status (1)

Country Link
WO (1) WO2016077639A2 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180177727A1 (en) 2015-06-10 2018-06-28 Board Of Regents, The University Of Texas System Use of exosomes for the treatment of disease
GB201609216D0 (en) * 2016-05-25 2016-07-06 Evox Therapeutics And Isis Innovation Ltd Exosomes comprising therapeutic polypeptides
MX2019013312A (en) 2017-05-08 2020-08-17 Flagship Pioneering Innovations V Inc Compositions for facilitating membrane fusion and uses thereof.
BR112020003354A2 (en) 2017-08-25 2020-08-18 Codiak Biosciences, Inc. preparation of therapeutic exosomes using membrane proteins
KR20200108275A (en) 2017-12-28 2020-09-17 코디악 바이오사이언시즈, 인크. Exosomes for immuno-oncology and anti-inflammatory therapy
MX2020008542A (en) 2018-02-17 2021-01-08 Flagship Pioneering Innovations V Inc Compositions and methods for membrane protein delivery.
WO2020102578A1 (en) 2018-11-14 2020-05-22 Flagship Pioneering Innovations V, Inc Compositions and methods for compartment-specific cargo delivery
WO2021046143A1 (en) 2019-09-03 2021-03-11 Sana Biotechnology, Inc. Cd24-associated particles and related methods and uses thereof
JP2023521663A (en) 2020-03-31 2023-05-25 サナ バイオテクノロジー，インコーポレイテッド TARGETED LIPID PARTICLES AND COMPOSITIONS AND USES THEREOF
CA3219487A1 (en) 2021-05-28 2022-12-01 Richard C. Mulligan Lipid particles containing a truncated baboon endogenous retrovirus (baev) envelope glycoprotein and related methods and uses
WO2024044655A1 (en) 2022-08-24 2024-02-29 Sana Biotechnology, Inc. Delivery of heterologous proteins
WO2024064838A1 (en) 2022-09-21 2024-03-28 Sana Biotechnology, Inc. Lipid particles comprising variant paramyxovirus attachment glycoproteins and uses thereof
WO2024081820A1 (en) 2022-10-13 2024-04-18 Sana Biotechnology, Inc. Viral particles targeting hematopoietic stem cells

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BANIZS ANNA B ET AL: "In vitro evaluation of endothelial exosomes as carriers for small interfering ribonucleic acid delivery.", INTERNATIONAL JOURNAL OF NANOMEDICINE 2014, vol. 9, 3 September 2014 (2014-09-03), pages 4223 - 4230, XP002754107, ISSN: 1178-2013 *
KAUR SUKHBIR ET AL: "CD47-dependent immunomodulatory and angiogenic activities of extracellular vesicles produced by T cells.", MATRIX BIOLOGY : JOURNAL OF THE INTERNATIONAL SOCIETY FOR MATRIX BIOLOGY JUL 2014, vol. 37, July 2014 (2014-07-01), pages 49 - 59, XP002754108, ISSN: 1569-1802 *
LYDIA ALVAREZ-ERVITI ET AL: "Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes", NATURE BIOTECHNOLOGY, vol. 29, no. 4, 20 March 2011 (2011-03-20), US, pages 341 - 345, XP055227686, ISSN: 1087-0156, DOI: 10.1038/nbt.1807 *

Also Published As

Publication number Publication date
WO2016077639A2 (en) 2016-05-19

Similar Documents

Publication Publication Date Title
WO2016077639A3 (en) Nanovesicular therapies
WO2015073587A3 (en) Synthetic membrane-receiver complexes
PH12016501809A1 (en) Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
EP3662903A3 (en) Combination therapies
PH12017500621A1 (en) Triazolopyrazinones as pde1 inhibitors
MX2020009780A (en) Autotaxin inhibitor compounds.
MX2019003623A (en) Compositions and methods for treating ophthalmic conditions.
MX2017002271A (en) Compositions and methods for treatment of neurological disorders.
GEP20247593B (en) Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders
GB2541571A (en) Pharmaceutical compositions
CA2900779C (en) Compositions and methods for treating neurodegenerative diseases and cardiomyopathy
MX2022007436A (en) Autotaxin inhibitors and uses thereof.
PH12017501990A1 (en) Imidazopyrazinones as pde1 inhibitors
MX2017002489A (en) Human therapeutic agents.
PH12016502530A1 (en) Pharmaceutical compositions comprising dgla and use of same
PH12016501371A1 (en) Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same
MX2017014456A (en) Therapeutic uses of l-4-chlorokynurenine.
PH12016501838A1 (en) Compounds and their methods of use
MX2021006439A (en) Cftr regulators and methods of use thereof.
PH12016501495A1 (en) Hexahydrofuropyrroles as pde1 inhibitors
EP3344337A4 (en) Methods and compositions for the treatment of cytopplasmic glycogen storage disorders
EP3199163A4 (en) Composition of doxycycline in liposomes for the prevention, improvement and/or treatment of ocular pathologies
WO2016144706A3 (en) Autotaxin inhibitor compounds and uses thereof
WO2016040313A3 (en) Methods of treating cancer comprising administering a ppar-gamma agonist
WO2015113041A3 (en) Compositions and methods for treating autoimmune and inflammatory diseases

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15802269

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 15802269

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 15802269

Country of ref document: EP

Kind code of ref document: A2